Ibandronate Sodium Catalog No.:M8787-2 Wnt-C59 was used to dose

Wnt-C59 was used to dose mice orally at 5-10 mg/kg once per day or 5 mg/kg twice per day

58 μM on HCT116 cells

7(8):1447-52

3 μM BDP5290 completely inhibits myosin II light chain (MLC) phosphorylation induced by MRCKβ

Ibandronate Sodium Catalog No.:M8787-2 Wnt-C59 was used to doseIbandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post menopausal women. In May 2003, the U. S. Food and Drug Administration (FDA) approved